Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

Look­ing to make a name for it­self out­side gene edit­ing and gene ther­a­py, Sang­amo has snapped up a pre­clin­i­cal biotech spe­cial­iz­ing in reg­u­la­to­ry T cells …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER